Economic evaluation of long term management strategies for erosive oesophagitis

PharmacoEconomics

Volumn 16, Issue 6, 1999, Pages 679-697

  Goeree, Ron ^a,b   O'Brien, Bernie ^a,b   Hunt, Richard ^a   Blackhouse, Gordon ^a,b   Willan, Andrew ^a,b   Watson, Jan ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b CENTRE FOR EVALUATION OF MEDICINES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CISAPRIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PLACEBO; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RANITIDINE;

ALGORITHM; ARTICLE; CONSULTATION; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; ENDOSCOPY; ESOPHAGITIS; HUMAN; MAINTENANCE THERAPY; PRIORITY JOURNAL; RADIODIAGNOSIS; RECURRENT DISEASE; TREATMENT OUTCOME;

EID: 0033454075     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199916060-00007     Document Type: Article

References (103)

1. Wienbeck M, Barnert J. Epidemiology of reflux disease and reflux oesophagitis. Scand J Gastroenterol 1989; 24: 7-13
2. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976; 21: 953-6
3. Richter J, Castell DO. Gastroesophageal reflux: pathogenesis, diagnosis and therapy. Ann Intern Med 1982; 97: 93-103
4. Heading RC. Epidemiology of oesophageal reflux disease. Scand J Gastroenterol 1989; 24: 33-7
5. Gallup Organization Inc. A Gallup Organization National Survey: heartburn across America. Princetown (NY): Gallup Organization Inc., 1988
6. Chiba N, Wilkinson J, Hunt RH. Symptom relief in erosive GERD: a meta-analysis [abstract]. Am J Gastroenterol 1993; 88: A1486
7. Chiba N, deGara CJ, Burget D, et al. Rapidity of healing in GERD: a comparison of different drug classes by meta-analysis [abstract]. Gastroenterology 1993; 104: A53
8. Department of Health, Housing and Community Services, Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including submissions involving economic analysis. Woden (ACT): Department of Health, Housing and Community Services, Commonwealth of Australia, 1990
9. Detsky A. Guidelines for preparation of economic analysis of pharmaceutical products: a draft document for Ontario and Canada. Pharmacoeconomics 1993; 321: 354-61
10. Leaf A. Cost-effectiveness as a criterion for Medicare coverage. N Engl J Med 1989; 321: 898-100
11. Weinstein MC, Fineberg HV. Clinical decision analysis. Philadelphia (PA): WB Saunders Company, 1980
12. Drummond MF, O'Brien BJ, Stoddart GL, et al. Methods for economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997
13. Anvari M, Allen C, Borm A. Laparoscopic nissen fundoplication is a satisfactory alternative to long-term omeprazole therapy. Br J Surg 1995; 82: 938-42
14. Beck IT, Connon J, Lemire S, et al. Canadian concensus conference on the treatment of gastroesophageal reflux disease. Can J Gastroenterol 1992; 6: 277-89
15. Sintonen H. Outcome measurement in acid-related diseases. Pharmacoeconomics 1994; 5: 17-26
16. Sintonen H, Alander V. Comparing the cost-effectiveness of drug regimens in the treatment of duodenal ulcers. J Health Econ 1990; 9: 85-101
17. DerSimonian R, Laird NM. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-8
18. Fliess JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993; 2: 121-45
19. Biggerstaff BJ, Tweedie RL. Incorporating variability in estimates of heterogeneity in the random effects model in meta-analysis. Stat Med 1997; 16: 753-68
20. Ministry of Health. Drug Benefit Formulary: Comparative Drug Index. No. 35, Toronto (ON): Publications Ontario, 1996
21. Ontario Ministry of Health. Schedule of Benefits: physician services under the Health Insurance Act. Toronto (ON): Ontario Ministry of Health, 1992
22. Ontario Hospital Association. Ontario Case Costing Project: Ontario guide to case costing. Toronto (ON): Ontario Hospital Association, 1995
23. O'Brien B, Goeree R, Hunt R, et al. Economic evaluation of alternative therapies in the long term management of peptic ulcer disease and gastroesophageal reflux disease: report to CCOHTA. Ottawa (ON): CCOHTA, 1996: 1-130. Report no.: RFP#9503-OMEP
24. Park RE, Fink A, Brook RH. Physician ratings of appropriate indications for six medical and surgical procedures. Am J Public Health 1986; 76: 766-72
25. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
26. Pharmacy Post. The 1996 Pharmacy Business Trends Report: a Pharmacy Post and Eli Lilly survey of community pharmacy in Canada. Toronto (ON): Pharmacy Post, 1996: 3-30
27. Baldi F, Bianchi Porro G, Dobrilla G, et al. Cisapride versus placebo in reflux esophagitis: a multicenter double-blind trial. J Clin Gastroenterol 1988; 10: 614-8
28. Galmiche JP, Fraitag B, Filoche B, et al. Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis. Dig Dis Sci 1990; 35: 649-55
29. Geldof H, Hazelhoff B, Otten MH. Two different dose regimens of cisapride in the treatment of reflux oesophagitis: a double-blind comparison with ranitidine. Aliment Pharmacol Ther 1993; 7: 409-15
30. Lepoutre L, Van dSP, Vanderlinden I, et al. Healing of grade-II and III oesophagitis through motility stimulation with cisapride. Digestion 1990; 45: 109-14
31. Maleev A, Mendizova A, Popov P, et al. Cisapride and cimetidine in the treatment of erosive esophagitis. Hepatogastroenterology 1990; 37: 403-7
32. Richter JE, Long JF. Cisapride for gastroesophageal reflux disease: a placebo- controlled, double-blind study. Am J Gastroenterol 1995; 90: 423-30
33. Robertson CS, Evans DF, Ledingham SJ, et al. Cisapride in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993; 7: 181-90
34. Elsborg L, Jorgensen F. Sucralfate versus cimetidine in reflux oesophagitis: a double-blind clinical study. Scand J Gastroenterol 1991; 26: 146-50
35. Farup PG, Weberg R, Berstad A, et al. Low-dose antacids versus 400 mg cimetidine twice daily for reflux oesophagitis: a comparative, placebo-controlled, multicentre study. Scand J Gastroenterol 1990; 25: 315-20
36. Fiasse R, Hanin C, Lepot A. Controlled trial of cimetidine in reflux esophagitis. Dig Dis Sci 1980; 25: 750-5
37. Breen KJ, Desmond PV, Whelan G. Treatment of reflux oesophagitis: a randomized, controlled evaluation of cimetidine. Med J Aust 1983; 2: 555-8
38. Galmiche JP, Brandstatter G, Evreux M, et al. Combine therapy with cisapride and cimetidine in severe reflux oesophagitis: a double blind controlled trial. Gut 1988; 29: 675-81
39. Bate CM, Keeling PW, O'Morain C, et al. Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations. Gut 1990; 31: 968-72
40. Dehn TC, Shepherd HA, Colin-Jones D, et al. Double blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24h pH monitoring. Gut 1990; 31: 509-13
41. Hameeteman W, Dekker W, Schrijver M, et al. Sucralfate versus cimetidine in reflux esophagitis: a single- blind multicenter study. J Clin Gastroenterol 1987; 9: 390-4
42. McCarty-Dawson D, Sue SO, Morrill B, et al. Ranitidine versus cimetidine in the healing of erosive esophagitis. Clin Ther 1996; 18: 1150-60
43. Palmer RH, Frank WO, Rockhold FW, et al. Cimetidine 800 mg twice daily for healing erosions and ulcers in gastroesophageal reflux disease. J Clin Gastroenterol 1990; 12 Suppl. 2: S29-34
44. Wesdorp E, Bartelsman J, Pape K, et al. Oral cimetidine in reflux oesophagitis: a double-blind controlled trial. Gastroenterology 1978; 74: 821-4
45. Bardhan KD, Hawkey CJ, Long RG, UK Lansoprazole Clinical Research Group, et al. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. Aliment Phamacol Ther 1995; 9: 145-51
46. Bianchi-Porro G, Pace F, Peracchia A, et al. Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine. J Clin Gastroenterol 1992; 15: 192-8
47. Bremner CG, Marks IN, Segal I, et al. Reflux esophagitis therapy: sucralfate versus ranitidine in a double blind multicenter trial. Am J Med 1991; 91: 119-22
48. Feldman M, Harford WV, Fisher RS, Lansoprazole Study Group, et al. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Am J Gastroenterol 1993; 88: 1212-7
49. Goy JA, Maynard JH, McNaughton WM, et al. Ranitidine and placebo in the treatment of reflux oesophagitis: a double-blind randomized trial. Med J Aust 1983; 2: 558-61
50. Guslandi M, Testoni PA, Passaretti S, et al. Ranitidine vs metoclopramide in the medical treatment of reflux esophagitis. Hepatogastroenterology 1983; 30: 96-8
51. Havelund T, Laursen LS, Skoubto-Kristensen E, et al. Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial. BMJ (Clin Res Ed) 1988; 296: 89-92
52. The Italian Reflux Oesophagitis Study Group. Omeprazole produces significantly greater healing of erosive or ulcerative reflux oesophagitis than ranitidine. Eur J Gastroenterol Hepatol 1991; 3: 511-7
53. Johnson NJ, Boyd EJ, Mills JG, et al. Acute treatment of reflux oesophagitis: a multicentre trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s. Aliment Pharmacol Ther 1989; 3: 259-66
54. Klinkenberg-Knol EC, Jansen JM, Festen HP, et al. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet 1987; 1: 349-51
55. Koop H, Schepp W, Dammann HG, et al. Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagilis: results of a German multicenter study. J Clin Gastroenterol 1995; 20: 192-5
56. Lehtola J, Niemela S, Martikainen J, et al. Ranitidine, 150 mg three times a day, in the treatment of reflux oesophagitis: a placebo-controlled, double-blind study. Scand J Gastroenterol 1986; 21: 175-80
57. Masci E, Testoni PA, Passaretti S, et al. Comparison of ranitidine, domperidone maleate and ranitidine + domperidone maleate in the short-term treatment of reflux oesophagitis. Drugs Exp Clin Res 1985; 11: 687-92
58. McKenna CJ, Mills JG, Goodwin C, et al. Combination of ranitidine and cisapride in the treatment of reflux oesophagitis. Eur J Gastroenterol Hepatol 1995; 7: 817-22
59. Pace F, Sangaletti O, Bianchi PG. Short and long-term effect of two different dosages of ranitidine in the therapy of reflux oesophagitis. Ital J Gastroenterol 1990; 22: 28-32
60. Richter JE, Sabesin SM, Kogut DG, et al. Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease. Am J Gastroenterol 1996; 91: 1766-72
61. Robinson M, Sahba B, Avner D, Multicentre Investigational Group, et al. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Aliment Pharmacol Ther 1995; 9: 25-31
62. Sandmark S, Carlsson R, Fausa O, et al. Omeprazole or ranitidine in the treatment of reflux esophagitis: results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol 1988; 23: 625-32
63. Schaub N, Meyrick TJ, Misiewicz JJ, et al. Investigation of ranitidine 150 mg bd or 300 mg bd in the treatment of reflux disease. Hepatogastroenterology 1986; 33: 208-13
64. Sherbaniuk R, Wensel R, Bailey R, et al. Ranitidine in the treatment of symptomatic gastroesophageal reflux disease. J Clin Gastroenterol 1984; 6: 9-15
65. Simon TJ, Berlin RG, Tipping R, Famotidine Erosive Esophagitis Study Group, et al. Efficacy of twice daily doses of 40 or 20 milligrams famotidine or 150 milligrams ranitidine for treatment of patients with moderate to severe erosive esophagitis. Scand J Gastroenterol 1993; 28: 375-80
66. Sontag SJ, Kogut DG, Fleischmann R, et al. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. Am J Gastroenterol 1997; 92: 429-37
67. Sontag S, Robinson M, McCallum RW, et al. Ranitidine therapy for gastroesophageal reflux disease: results of a large double-blind trial. Arch Intern Med 1987; 147: 1485-91
68. Vantrappen G, Rulgeerts L, Schurmans P, et al. Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis. Dig Dis Sci 1988; 33: 523-9
69. Wesdorp ICE, Dekker W, Klinkenberg-Knol EC. Treatment of reflux oesophagitis with ranitidine. Gut 1983; 24: 921-4
70. Zeitoun P, Rampal P, Barbier P, et al. Omeprazole (20 mg daily) compared to ranitidine (150 mg twice daily) in the treatment of esophagitis caused by reflux: results of a double-blind randomized multicenter trial in France and Belgium. Gastroenterol Clin Biol 1989; 13: 457-62
71. Euler AR, Murdock Jr RH, Wilson TH, et al. Ranitidine is effective therapy for erosive esophagitis. Am J Gastroenterol 1993; 88: 520-4
72. Lundell L. Prevention of relapse of reflux oesophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Digestion 1990; 47 Suppl. 1: 72-5
73. Roufail W, Belsito A, Robinson M, et al. Ranitidine for erosive esophagitis: a double-blind, placebo-controlled study. Aliment Pharmacol Ther 1992; 6: 597-607
74. Silver MT, Murdock RH, Morrill BB, et al. Ranitidine 300 mg twice daily and 150 mg four-times daily are effective in healing erosive oesophagitis. Aliment Pharmacol Ther 1996; 10: 373-80
75. Castell DO, Richter JE, Robinson M, The Lansoprazole Group, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol 1996; 91: 1749-57
76. Hatlebakk JG, Berstad A, Carling L, et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. results of a Scandinavian multicentre trial. Scand J Gastroenterol 1993; 28: 224-8
77. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903-12
78. Mee AS, Rowley JL. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther 1996; 10: 757-63
79. Mossner J, Holscher AH, Herz R, et al. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther 1995; 9: 321-6
80. Robinson M, Decktor DL, Maton PN, et al. Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis. Aliment Pharmacol Ther 1993; 7: 67-73
81. Sontag SJ, Hirschowitz BI, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study. Gastroenterol 1992; 102 (1): 109-18
82. Mulder CJ, Dekker W, Gerretsen M, Dutch Study Group. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Eur J Gastroenterol Hepatol 1996; 8: 1101-6
83. Robinson M, Campbell DR, Sontag S, et al. Treatment of erosive reflux esophagitis resistant to h2-receptor antagonist therapy: lansoprazole, a new proton pump inhibitor. Dig Dis Sci 1995; 40: 590-7
84. Dent J. Australian clinical trials of omeprazole in the management of reflux oesophagitis. Digestion 1990; 47 Suppl. 1: 69-71
85. Bardhan KD, Cherian P, Vaishnavi A, et al. Erosive esophagitis (EE): outcome of repeated longterm treatment with low dose omeprazole (OM) 10 mg or placebo (PLA) [abstract]. Gastroenterology 1995; 108: A53
86. Bate CM, Booth SN, Crowe JP, Solo Investigator Group, et al. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesphagitis. Gut 1995; 36: 492-8
87. Blum AL, Adami B, Bouzo MH, Italian Eurocis Trialists, et al. Effect of cisapride on relapse of esophagitis: a multinational, placebo-controlled trial in patients healed with an antisecretory drug. Dig Dis Sci 1993; 38: 551-60
88. Hegarty JH, Halvorsen L, Hazenberg BP, et al. Prevention of relapse in reflux esophagitis: a placebo controlled study of ranitidine 150 mg bid and 300 mg bid. Can J Gastroenterol 1997; 11: 83-8
89. Laursen LS, Havelund T, Bondesen S, et al. Omeprazole in the long-term treatment of gastro-oesophageal reflux disease: a double-blind randomized dose-finding study. Scand J Gastroenterol 1995; 30: 839-46
90. Koelz HR, Birchler R, Bretholz A, et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology 1986; 91: 1198-205
91. Robinson M, Lanza F, Avner D, et al. Effective maintenance treatment of reflux esophagitis with low- dose lansoprazole: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 124: 859-67
92. Sontag S, Robinson M, Roufail W, et al. Daily omeprazole (OME) is needed to maintain healing in erosive esophagitis (EE): a U.S., multicenter double-blind study [abstract #65]. Am J Gastroenterol 1992; 87: 1258
93. Sontag SJ, Kogut DG, Fleischmann R, The Lansoprazole Maintenance Study Group, et al. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. Am J Gastroenterol 1996; 91: 1758-65
94. Toussaint J. Relapse prevention of esophagitis with cisapride: a multicentre placebo-controlled study. J Drug Dev 1993; 5: 15-9
95. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-10
96. Pace F, Lazzaroni M, Bianchi PG. Failure of sucralfate in the treatment of refractory esophagitis versus high-dose famotidine: an endoscopic study. Scand J Gastroenterol 1991; 26: 491-4
97. Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis: a controlled double blind trial of their efficacy and safety. Gut 1994; 35: 590-8
98. Hallerback B, Unge P, Carling L, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis: the Scandinavian clinics for United Research Group. Gastroenterology 1994; 107: 1305-11
99. Lundell L, Backman L, Ekstrom P, et al. Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol 1991; 26: 248-56
100. Zeitoun P, Barbier P, Cayphas J-P, et al. Comparison of low dosage regimens of Omeprazole - 10 mg once daily and 20 mg weekends - as prophylaxis against recurrence of reflux esophagitis [abstract F15]. Hepatogastroenterol 1989; 36: 279
101. Baldi F, Bardhan KD, Borman BC, et al. Lansoprazole maintains healing in patients with reflux esophagitis [abstract]. Gastroenterology 1996; 110; A55
102. Gough AL, Long RG, Cooper BT, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996; 10: 529-39
103. Carling L, Axelsson CK, Forsell H, et al. Lansoprazole vs omeprazole in long term maintenance treatment of refluzoesophagitis: a Scandinavian multicentre trial [abstract 1036]. Gut 1996; 39: A182